Grammar:		DataElement 5.0
Namespace:		oncology
Description:	"SHR implementation of ASCO requirements."
Uses:  			shr.core, shr.base, cimi, finding, entity, condition

CodeSystem:     SCT = http://snomed.info/sct
CodeSystem:     LNC = http://loinc.org
CodeSystem:		MTH = http://ncimeta.nci.nih.gov
CodeSystem:     UCUM = http://unitsofmeasure.org
//CodeSystem:		HGNC = http://www.genenames.org
CodeSystem:		OBSCAT = http://hl7.org/fhir/observation-category
CodeSystem:		CAP = https://sdt.cap.org
//

EntryElement:	BreastSite
Based on:		AnatomicalLocation
Description:	"A body site specific to the breast structure."
Value:			CodeableConcept from BreastSiteVS
0..1			ClockDirection
0..1			DistanceToNipple
				Laterality from LeftRightLateralityVS
0..0			Directionality
0..0			PortionTotality

		Element:		DistanceToNipple
		Description:	"The body site location in relation to the nipple."
		Value:			Quantity with units UCUM#cm

		
EntryElement:	BreastSpecimen
Based on:		Specimen
Description:	"Specimen resulting from biopsy or excision of breast and surrounding tissue."
				Type from BreastSpecimenTypeVS
				CollectionSite value is type BreastSite
				CollectionMethod from BreastSpecimenCollectionMethodVS
				SourceSpecimen value is type BreastSpecimen
0..1			ColdIschemiaTime

		Element:	 	ColdIschemiaTime
		Description:	"The time between the chilling of a tissue or tissue sample and the time it is warmed. 
		NOTE: In CIMI Version 0.0.4, processing of a specimen is represented as an independent clinical statement involving a SpecimenProcessingTopic and PerformanceContext. The CIMI clinical statement would be mapped to FHIR as a Procedure. In this case, the procedure involves chilling the specimen (the key or code) and the duration of that procedure (corresponding to PerformanceContext.duration) would be interpreted as the cold ischemic time. The drawback of this would be that the information on cold ischemic time (necessary for interpreting results) would not travel with the specimen. To provide a cutpoint between this IG and the rest of CIMI, and to avoid unnecessary complexity, an extension was introduced."
		Value:			Quantity with units UCUM#min

EntryElement:	BreastRegionalLymphNodeSpecimen
Based on:		BreastSpecimen
Concept:		TBD
Description:	"The removal of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event. This model is yet to be determined."
// To be determined

EntryElement:	BreastCancerPresenceStatement
Concept:		SCT#126926005 "Neoplasm of the breast"
Based on:		ConditionPresenceStatement  
Description:	"FindingTopic or diagnosis of cancer originating in the tissues of the breast, and potentially spread to other organs of the body.

The BreastCancerPresenceStatement is a subclass of ConditionPresenceStatement, which is a departure from CIMI. In CIMI, this would be a archetype of ClinicalStatement combining a BreastCancerConditionTopic with the ConditionPresenceContext. This would require definition of BreastCancerConditionTopic in the reference model, follwed by introduction of constraints on Value, Category, Stage, and MorphologyBehavior in the corresponding archetype."
Value:			CodeableConcept from BreastCancerTypeVS
				Category includes #disease
				ConditionPresenceContext.Stage from BreastCancerStageVS				
				ConditionPresenceContext.Stage.StageDetail value is type BreastCancerPrognosticStage
				FindingMethod from BreastCancerDetectionVS
0..1			MorphologyBehavior from MorphologyBehaviorVS

			Element:		MorphologyBehavior
			Concept:		TBD
			Description:	"A description of the morphology characteristics of the cancer."
			Value:			CodeableConcept

EntryElement:	BreastCancerPrognosticStage
Based on:		EvaluationResultRecorded  // maps to FHIR Observation
Concept:		LNC#21908-9
Description:	"The prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada."
Value:			CodeableConcept from BreastCancerStageVS 
1..1			FindingMethod from StagingMethodVS
1..1			StageTimingPrefix from StageTimingPrefixVS
				EvaluationComponent			
includes 0..1 	BreastCancerTCategory
includes 0..1 	BreastCancerNCategory
includes 0..1 	BreastCancerMCategory
				Members.EvaluationResultTopic
includes 1..1	HER2ReceptorStatus
includes 1..1	EstrogenReceptorStatus
includes 1..1	ProgesteroneReceptorStatus
includes 0..1	NuclearGrade
includes 0..1	HistologicGrade	

		Element:		StageTimingPrefix
		Concept:		TBD
		Description:	"Mandatory element indicating when the staging was done, in terms of treatment landmarks, either clinical (at diagnosis prior to treatment) (c), pathologic (post-surgical) (p), post-neoadjuvant clinical (yc), or post-neoadjuvant pathologic(yp). The stage timing code is prefix on the N stage. For example, for post-neoadjuvant clinical staging, the N categories are preceded by 'yc' (e.g. ycNX)"
		Value:			CodeableConcept	
		
		Element:		BreastCancerTCategory
		Concept:		LNC#59528-0
		Based on:		EvaluationComponent
		Description:	"The size and extent of the primary tumor (greatest dimension), based on criteria from the American Joint Committee on Cancer."
		Value:			CodeableConcept from BreastCancerTCategoryVS
		0..0			ReferenceRange

		Element:		BreastCancerNCategory
		Concept:		LNC#59525-6
		Based on:		EvaluationComponent
		Description:	"The presence of metastases in regional lymph nodes. The node category for staging is based on criteria from the American Joint Committee on Cancer."
		Value:			CodeableConcept from BreastCancerNCategoryVS
		0..0			ReferenceRange

		Element:		BreastCancerMCategory
		Concept:		LNC#59522-3
		Based on:		EvaluationComponent
		Description:	"Part of the TNM classification system representing metastases.  The system is used to describe the spread of cancer to other parts of the body."
		Value:			CodeableConcept from BreastCancerMCategoryVS
		0..0			ReferenceRange

EntryElement:	NuclearGrade
Concept:		MTH#C18513
Based on: 		SimplifiedLaboratoryTestResultRecorded
Description:	"An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade."
Value:			CodeableConcept from NuclearGradeVS
				Specimen is type BreastSpecimen
				TopicCode is MTH#C18513
0..0			EvaluationComponent

EntryElement:	HistologicGrade
Concept:		LNC#44648-4
Based on:		SimplifiedLaboratoryTestResultRecorded
Description:	"The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing."
Value:			CodeableConcept from NottinghamCombinedGradeVS
				TopicCode is LNC#44648-4
				DiagnosticService is #pathology
				Specimen is type BreastSpecimen
				EvaluationComponent
includes 0..1 	TubuleFormationScore
includes 0..1 	NuclearPleomorphismScore
includes 0..1 	MitoticCountScore

			Element:		TubuleFormationScore
			Concept:		SCT#371470008
			Based on:		EvaluationComponent
			Description:	"A comparison between structures formed by the tumor cells as opposed to those formed by normal cells. Scored 1 to 3 with 3 being the most abnormal."
			Value:			CodeableConcept from TubuleFormationScoreVS  //TODO: Determine if it is better to use codes as opposed to a number 1, 2 or 3. Observations don't support integer or posInteger
			0..0			ReferenceRange

			Element:		NuclearPleomorphismScore
			Concept:		TBD
			Based on:		EvaluationComponent
			Description:	"How large and varied the nuclei of the tumor cells are. Scored 1 to 3, with 3 being the most pleomorphism."
			Value:			CodeableConcept from NuclearPleomorphismScoreVS
			0..0			ReferenceRange

			Element:		MitoticCountScore
			Concept:		SCT#371472000
			Based on:		EvaluationComponent
			Description:	"How fast the tumor cells are growing and dividing, determined from the number of mitotic cells present. Scored 1 to 3, with 3 being the most mitotic cells."
			Value:			Quantity   // 1 to 3
			0..0			ReferenceRange

//			includes 0..1	PercentageInSituCarcinoma   // not sure where this belongs


EntryElement:	EstrogenReceptorStatus
Based on:		SimplifiedLaboratoryTestResultRecorded
Concept:		LNC#16112-5 "Estrogen receptor [Interpretation] in Tissue"
Description:	"Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.

We are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The point of view expressed in this model is that positive/negative designation is an interpretation, based on evidence such as NuclearPositivity and AverageStainingIntensity, not a direct result. This also appears to be the most consistent approach across all receptor statuses (ER, PR, and HER2)."
Value:			PercentageRange
				Interpretation from PositiveNegativeVS
				TopicCode is LNC#16112-5
				DiagnosticService is #pathology	
				Specimen is type BreastSpecimen				
				EvaluationComponent
//includes 0..1	NuclearPositivity
includes 0..1	AverageStainingIntensity


EntryElement:	ProgesteroneReceptorStatus
Based on:		SimplifiedLaboratoryTestResultRecorded
Concept:		LNC#16113-3
Description:	"Progesterone receptor status is a factor in determining prognosis and treatment options. The value is the percentage of cells that test (stain) positive for the presence of a receptor. The interpretation of positive or negative (found in the interpretation property) is based on the staining percentage, and may take into account the staining intensity. 

Based on discussion with Cancer Interoperability Group subject matter experts, there was insufficient rationale to include the following components in the data model: StainingControl, PrimaryAntibody, Allred Score (both total and component scores). We are seeking feedback on whether or not those components should be included in this model.

We are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The point of view expressed in this model is that positive/negative designation is an interpretation, based on evidence such as NuclearPositivity and AverageStainingIntensity, not a direct result. This also appears to be the most consistent approach across all receptor statuses (ER, PR, and HER2)."
Value:			PercentageRange
				Interpretation from PositiveNegativeVS
				TopicCode is LNC#16113-3 "Progesterone receptor [Interpretation] in Tissue"	
				DiagnosticService is #pathology	
				Specimen is type BreastSpecimen				
				EvaluationComponent
//includes 0..1	NuclearPositivity
includes 0..1	AverageStainingIntensity

/*
		Element:		NuclearPositivity
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"The percentage of cells that test (stain) positive for the presence of a receptor."
		Value:			PercentageRange
		0..0			ReferenceRange
*/			
		Element:		AverageStainingIntensity
		Concept:		SCT#444775005 "Average intensity of positive staining neoplastic cells (observable entity)"
		Based on:		EvaluationComponent
		Description:	"The degree or magnitude of staining (nuclear positivity) across cells in the specimen."
		Value:			CodeableConcept from StainingIntensityVS
		0..0			ReferenceRange

		
EntryElement:	HER2ReceptorStatus
Based on:		LaboratoryTestResultRecorded
Concept:		LNC#48676-1 "HER2 [Interpretation] in Tissue"
Description:	"HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors,10 and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.

We are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The point of view expressed in this model is that positive/negative designation is an interpretation of HER2 by IHC and HER2 by ISH tests, not a direct result. This also appears to be the most consistent approach across all receptor statuses (ER, PR, and HER2)."
0..0			Value
0..0			ExceptionValue
				Interpretation from PositiveNegativeEquivocalVS
				TopicCode is LNC#48676-1 "HER2 [Interpretation] in Tissue"
				Category is OBSCAT#laboratory
				DiagnosticService is #pathology
				Specimen is type BreastSpecimen
//0..0			Focus
0..0			Precondition
0..0			ReferenceRange
0..0			AnatomicalLocation // AnatomicalLocation is covered in the Specimen collection
0..0			FindingMethod
				Members.EvaluationResultTopic
includes 0..*	HER2byIHC
includes 0..*	HER2byISH
				
EntryElement:	HER2byIHC
Based on:		EvaluationResultRecorded
Concept:		LNC#72383-3
Description:	"HER2 receptor status as determined by Immunohistochemistry (IHC)."
Value:			CodeableConcept from HER2byIHCScoreVS
				TopicCode is LNC#72383-3 "HER2 Presence in Tissue by Immunoassay"
				FindingMethod from HER2IHCMethodVS
				Interpretation from PositiveNegativeEquivocalVS
				EvaluationComponent
includes 0..1	CompleteMembraneStainingPercent
//includes 0..1	PrimaryAntibody  // from HER2AntibodyIHCVS if covered

		Element:		CompleteMembraneStainingPercent
		Based on:		EvaluationComponent
		Concept:		LNC#16112-5  "Cells.HER2 uniform intense membrane staining/100 cells"
		Description:	"Percentage of cells with uniform intense complete membrane staining."
		Value:			Quantity with units UCUM#%   // TODO: Percentage causes CLI error
		0..0			ReferenceRange
		
EntryElement:	HER2byISH
Based on:		EvaluationResultRecorded
Concept:		LNC#72383-3
Description:	"HER2 receptor status as determined by In Situ Hybridization (ISH)."
				TopicCode is LNC#72383-3 "HER2 Presence in Tissue by Immunoassay"
				FindingMethod from HER2ISHMethodVS
				Interpretation from PositiveNegativeEquivocalVS
				EvaluationComponent
includes 0..1	AverageHER2SignalsPerCell
includes 0..1	AverageCEP17SignalsPerCell
includes 0..1	HER2toCEP17Ratio
includes 0..1	Aneusomy
includes 0..1	HeterogeneousSignals
includes 0..1	PercentageAmplified

		Element:		AverageHER2SignalsPerCell
		Based on:		EvaluationComponent
		Concept:		LNC#74860-8
		Description:	"Average number of HER2 signals per cell"
		Value:			Quantity
		0..0			ReferenceRange
		
		Element:		AverageCEP17SignalsPerCell
		Based on:		EvaluationComponent
		Concept:		LNC#74861-6
		Description:	"Average number CEP17 signals per cell (dual probe only)"
		Value:			Quantity
		0..0			ReferenceRange
		
		Element:		HER2toCEP17Ratio
		Based on:		EvaluationComponent
		Concept:		LNC#49683-6
		Description:	"HER2 to CEP17 Ratio (dual probe only)"
		Value:			Quantity
		0..0			ReferenceRange
		
		Element:		Aneusomy
		Based on:		EvaluationComponent
		Concept:		CAP#30478
		Description:	"Aneusomy (as defined by vendor kit used)"
		Value:			CodeableConcept from YesNoVS
		0..0			ReferenceRange
	
		Element:		HeterogeneousSignals
		Based on:		EvaluationComponent
		Concept:		CAP#30482 
		Description:	"Whether In Situ Hybridization signals were heterogeneous."
		Value:			CodeableConcept from YesNoVS
		0..0			ReferenceRange
		
		Element:		PercentageAmplified
		Based on:		EvaluationComponent
		Concept:		CAP#31073
		Description:	"Percentage of cells with amplified HER2 signals"
		Value:			Quantity with units UCUM#%
		0..0			ReferenceRange

		
EntryElement:	OncotypeDxInvasiveRecurrenceScore
Based on:		SimplifiedLaboratoryTestResultRecorded
Concept:		MTH#C1709318
Description:	"The Oncotype DX test for invasive breast cancer examines the activity of 21 genes in a patientâ€™s breast tumor tissue to provide personalized information for tailoring treatment based on the biology of their individual disease. The value is 0 to 100 indicates the estimated risk of recurrence with highest risk indicated by score > 31.

No LOINC code currently exists for this test."
Value: 			Quantity with units UCUM#1
				TopicCode is MTH#C1709318
				Interpretation from OncotypeDxInvasiveRiskScoreInterpretationVS
				DiagnosticService is #pathology
				Specimen is type BreastSpecimen
0..0			EvaluationComponent				

EntryElement:	OncotypeDxDCISRecurrenceScore
Based on:		SimplifiedLaboratoryTestResultRecorded
Concept:		MTH#C3898101
Description:	"The Oncotype DX test for DCIS (Ductal Carcinoma in Situ) breast cancer. Risk scores are range from 0 to 100 with the following interpretations: 0-38: Low-Risk, 39-54: Intermediate-Risk, 55+: High-Risk.

No LOINC code currently exists for this test."
Value: 			Quantity with units UCUM#1
				TopicCode is MTH#C3898101
				Interpretation from OncotypeDxDCISRiskScoreInterpretationVS
				DiagnosticService is #pathology
				Specimen is type BreastSpecimen	
0..0			EvaluationComponent
				
EntryElement:	ProsignaRecurrenceScore
Based on:		SimplifiedLaboratoryTestResultRecorded
Concept:		LNC#76544-6
Description:	"Breast cancer genomic signature assay for 10-year risk of distant recurrence score calculated by Prosigna.

The Prosigna Score is reported on a 0 -100 scale (referred to as ROR Score or Risk of Recurrence Score in the literature), which is correlated with the probability of distant recurrence at ten years for post-menopausal women with hormone receptorpositive, early stage breast cancer."
Value: 			Quantity with units UCUM#1
				TopicCode is LNC#76544-6
				Interpretation from RecurrenceRiskScoreInterpretationVS
				DiagnosticService is #pathology
				Specimen is type BreastSpecimen
0..0			EvaluationComponent				
				
EntryElement:	MammaprintRecurrenceScore
Based on:		SimplifiedLaboratoryTestResultRecorded
Concept:		MTH#C2827401
Description:	"Breast cancer genomic signature assay for 10-year risk of distant recurrence score calculated by Mammaprint.

In the United States, MammaPrint can only be used on cancers that are stage I or stage II, invasive, smaller than 5 centimeters, and estrogen-receptor-positive or -negative. Scores range from -1.0 to +1.0, with scores less than 0 indicating high risk, and scores greater than 0 indicating low risk.

The is currently no LOINC code for Mammaprint test."
Value: 			Quantity
				TopicCode is MTH#C2827401
				Interpretation from MammaprintRiskScoreInterpretationVS
				DiagnosticService is #pathology
				Specimen is type BreastSpecimen				 
0..0			EvaluationComponent
	
EntryElement: 	TumorDimensions
Based on:		LaboratoryTestResultRecorded   /// Imaging???
Concept:		MTH#C4086369
0..0			Value
0..0			ExceptionValue
//				Focus is type Tumor
// 				AnatomicalLocation ???
				TopicCode is MTH#C4086369
				DiagnosticService is #pathology
				EvaluationComponent
includes 0..1	TumorPrimaryDimensionSize
includes 0..1	TumorSecondaryDimensionSize
includes 0..1	SizeOfGrossTumorBed

		Element:		TumorPrimaryDimensionSize
		Description:	"The longest diameter of the primary tumor."
		Based on:		EvaluationComponent
		Concept:		LNC#33728-7
		Value:			Quantity with units UCUM#mm	
		0..0			ReferenceRange		
		
		Element:		TumorSecondaryDimensionSize
		Description:	"The longest perpendicular diameter of the primary tumor."
		Based on:		EvaluationComponent
		Concept:		LNC#33729-5
		Value:			Quantity with units UCUM#mm
		0..0			ReferenceRange

		Element:		SizeOfGrossTumorBed
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"The largest dimension of the gross tumor bed/fibrotic area."
		Value:			Quantity with units UCUM#mm
		0..0			ReferenceRange


EntryElement: 	TumorMargins
Based on:		SimplifiedLaboratoryTestResultRecorded
Concept:		MTH#C4086369
Description:	"The edge or border of the tissue removed in cancer surgery. The margin is described as negative or clean when the pathologist finds no cancer cells at the edge of the tissue, suggesting that all of the cancer has been removed. The margin is described as positive or involved when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed."
Value: 			CodeableConcept from PositiveNegativeVS
				TopicCode is MTH#C4086369
				DiagnosticService is #pathology
				Specimen is type BreastSpecimen	
				EvaluationComponent
includes 0..1	TumorMarginDescription
includes 0..1	Cellularity   // not sure this belongs here
includes 0..1	PercentageInSituCarcinoma   // not sure this belongs here
// Do we need to record the method? whether the result of imaging, or study of a removed tumor after lumpectomy?	

		Element:		TumorMarginDescription
		Concept:		TBD
		Based on:		EvaluationComponent
		Description:	"Description of the edge or border of tumor in situ by radiologist or of removed tumor by pathologist."
		Value:			CodeableConcept from TumorMarginDescriptionVS
		0..0			ReferenceRange

		Element:		Cellularity
		Concept:		MTH#C4055283
		Based on:		EvaluationComponent
		Description:	"Percentage of cells in a sample that are cancerous"
		Value:			Quantity with units UCUM#%
		0..0			ReferenceRange

		Element:		PercentageInSituCarcinoma
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"The percentage of the cancer that is in situ, as opposed to invading other tissues."
		Value:			Quantity with units UCUM#%
		0..0			ReferenceRange

	
EntryElement:	LymphaticInvolvement
Based on:		LaboratoryTestResultRecorded
Concept:		MTH#C0746333
Description:	"Description of lymph nodes contain cancer cells."
Value:			CodeableConcept from PositiveNegativeVS
				TopicCode is MTH#C0746333
1..1			AnatomicalLocation from LymphSystemSubdivisionVS 
				DiagnosticService is #pathology
				Specimen is type BreastRegionalLymphNodeSpecimen
//0..0			Focus
0..0			Precondition
0..0			ReferenceRange
0..0			Members.EvaluationResultTopic
0..0			DeltaFlag
				EvaluationComponent
includes 0..1 	LargestLymphNodeSize
includes 0..1 	NumberOfLymphNodesInvolved
includes 0..1 	DegreeOfLymphaticInvolvement

		Element:		LargestLymphNodeSize
		Based on:		EvaluationComponent
		Concept:		MTH#C1285847
		Description:	"The largest dimension of the largest lymph node invaded by cancer cells."
		Value: 			Quantity with units UCUM#mm
		0..0			ReferenceRange
						
		Element:		NumberOfLymphNodesInvolved
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"A count of lymph nodes invaded by cancer cells of those examined."
		Value:			Quantity with units UCUM#1
		0..0			ReferenceRange

		Element:		DegreeOfLymphaticInvolvement
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"Assessment of how much cancer is in a lymph node."
		Value:			CodeableConcept from DegreeOfLymphaticInvolvementVS
		0..0			ReferenceRange


	Element: 		Ki-67LabelingIndex
	Based on:		SimplifiedLaboratoryTestResultRecorded		
	Concept:		LNC#33055-5
	Description:	"Ki-67 is a protein phosphatase whose expression is strongly associated with cell proliferation and encoded by the MKI67 gene. The Ki67 labeling index is the fraction of Ki-67-positive cells to total cells in a tumor specimen and may be useful for determining prognosis with respect to survival and disease recurrence. The more positive cells there are, the more quickly they are dividing and forming new cells.	ReferenceRange: Low <10, Intermediate 10-20, >20 High"
	Value:		 	Quantity with units UCUM#%
					TopicCode is LNC#33055-5
					DiagnosticService is #pathology
	0..0			EvaluationComponent
	//includes 0..1	PrimaryAntibody  //from Ki67AntibodyVS if covered

	Element:		S-PhaseFraction
	Based on:		SimplifiedLaboratoryTestResultRecorded
	Concept:		LNC#30913-8
	Description: "An expression of the number of mitoses found in a stated number of cells. The S-phase fraction number tells you what percentage of cells in the tissue sample are in the process of copying their genetic information (DNA). This S-phase, short for synthesis phase, happens just before a cell divides into two new cells. ReferenceRange: Low <6, Intermediate 6-10, >10 High."
	Value:			Quantity with units UCUM#%
					TopicCode is LNC#30913-8
					DiagnosticService is #pathology
	0..0			EvaluationComponent				
					
/*  Out of scope for ballot
EntryElement:	GeneticVariant
Based on:		LaboratoryTestResultRecorded
Concept:		MTH#C3263354
Description:	"Whether a subject carries a mutation in a particular gene."
Value:			CodeableConcept from PositiveNegativeVS
				Focus.CodeableConcept from GeneIdentifierVS
				DiagnosticService is #genetics
				TopicCode is MTH#C3263354
0..0			Precondition
0..0			ReferenceRange
0..0			Members.EvaluationResultTopic
0..0			DeltaFlag
0..0			AnatomicalLocation
				EvaluationComponent
includes 0..1	Refseq

			Element:		Refseq
			Based on:		EvaluationComponent
			Concept:		TBD
			Description:	"The Reference Sequence (RefSeq) collection provides a comprehensive, integrated, non-redundant, well-annotated set of sequences, including genomic DNA, transcripts, and proteins. RefSeq sequences form a foundation for medical, functional, and diversity studies. They provide a stable reference for genome annotation, gene identification and characterization, mutation and polymorphism analysis (especially RefSeqGene records), expression studies, and comparative analyses."
			Value: 			CodeableConcept from RefseqVS


EntryElement:	BreastCancerGeneticAnalysisPanel
Concept:		MTH#C2708453
Based on:		LaboratoryTestResultRecorded
Description:	"The status of genes known or suspected to play a role in breast cancer risk, for example, the tumor suppressor genes, BRCA1 and BRCA2."
0..0			Value
				TopicCode is MTH#C2708453
				DiagnosticService is #genetics
0..0			Precondition
0..0			ReferenceRange
0..0			DeltaFlag
0..0			AnatomicalLocation
0..0			EvaluationComponent
				Members.EvaluationResultTopic
includes 1..1	BRCA1Variant
includes 1..1	BRCA2Variant

	Element:		BRCA1Variant
	Concept:		MTH#C2010863
	Based on:		GeneticVariant
	Description:	"Whether the patient has a mutation in the BRCA1 gene."
	Value:			CodeableConcept from PositiveNegativeVS
					Focus.CodeableConcept is HGNC#BRCA1Gene
					TopicCode is MTH#C2010863
					
	Element:		BRCA2Variant
	Concept:		MTH#C2010864
	Based on:		GeneticVariant
	Description:	"Whether the patient has a mutation in the BRCA2 gene."
	Value:			CodeableConcept from PositiveNegativeVS
					Focus.CodeableConcept is HGNC#BRCA2Gene
					TopicCode is MTH#C2010864

*/

/*
FHIR Genomics:
https://www.hl7.org/FHIR/2016Jan/obs-genetics-example3-bcr1%20and%20bcr2%20sequencing%20with%20FamilyHistory%20-1.json.html
https://www.hl7.org/FHIR/2016Jan/observation-genetics-cg-prf-1a.html
https://www.hl7.org/FHIR/2016Jan/observation-genetics.html
https://www.hl7.org/FHIR/2016Jan/obs-genetics-example2-germline.html
*/